Announcements Trials
Browse Landscape

Phase

Phase 2 102Phase 3 20Phase 1/2 15Phase 1 10Phase NA 6Phase 2/3 5Phase 4 4Phase EARLY_PHASE1 2

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 2Gastrointestinal 2Breast 2Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Neoplasms 2Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoproliferative Disorders 1Lung Neoplasms 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × pertuzumab × Clear all
NCT05786716 2025-12-02

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
825 enrolled
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

NCT02568839 2020-08-13

PREDIX HER2

Karolinska University Hospital

Phase 2/3 Active not recruiting
202 enrolled
Breast

Breast Neoplasms

NCT02581462 2020-08-11

PETRARCA

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2/3 Completed
81 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡